Trial
NCT01055301
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
SWOG Cancer Research Network
Collaborators
National Cancer Institute (NCI)
Condition
Multiple Myeloma
Intervention
bortezomib
Why stopped
lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-06